Novo Nordisk Research Center Seattle, Inc., Seattle, WA, USA.
Novo Nordisk Research Center Seattle, Inc., Seattle, WA, USA.
Cell Metab. 2019 Apr 2;29(4):795-802. doi: 10.1016/j.cmet.2019.02.004. Epub 2019 Mar 14.
Recent articles have highlighted the lack of reproducibility of data from scientific publications. Here we would argue that a better way to describe and also tackle this matter is to use the term "lack of robustness," since it points toward potential solutions. Presenting several case reports, we highlight examples with common underlying issues from Novo Nordisk's experience: animal model variability, reagent quality, and inter-lab variability. We discuss means to prevent these issues and argue for increased collaborative work and transparent manuscript revision procedures. Collectively, we believe these measures will help promote a more rapid and efficient self-corrective process in diabetes drug target research.
最近的一些文章强调了科学出版物的数据再现性差的问题。在这里，我们认为使用“缺乏稳健性”这个术语来描述和解决这个问题更好，因为它指向潜在的解决方案。通过呈现几个案例报告，我们强调了诺和诺德经验中常见的潜在问题：动物模型变异性、试剂质量和实验室间变异性。我们讨论了预防这些问题的方法，并主张增加合作工作和透明的手稿修订程序。总的来说，我们相信这些措施将有助于促进糖尿病药物靶点研究中更快、更有效的自我修正过程。
